71 related articles for article (PubMed ID: 3349938)
1. [Immunotherapy of advanced pancreatic carcinoma with the monoclonal antibody BW 494].
Büchler M; Kübel R; Malfertheiner P; Friess H; Schulz G; Bosslet K; Beger HG
Dtsch Med Wochenschr; 1988 Mar; 113(10):374-80. PubMed ID: 3349938
[TBL] [Abstract][Full Text] [Related]
2. [Therapy of pancreatic carcinoma with the monoclonal antibody BW 494/32: first clinical results].
Friess H; Büchler M; Schulz G; Beger HG
Immun Infekt; 1989 Feb; 17(1):24-6. PubMed ID: 2925220
[TBL] [Abstract][Full Text] [Related]
3. Generation and application of monoclonal antibody to human pancreatic carcinoma.
Yuan S; Zhang H; Chen Q
Hybridoma; 1996 Aug; 15(4):289-93. PubMed ID: 8880216
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of pancreatic cancer with monoclonal antibody BW 494.
Schulz G; Büchler M; Muhrer KH; Klapdor R; Kübel R; Harthus HP; Madry N; Bosslet K
Int J Cancer Suppl; 1988; 2():89-94. PubMed ID: 3162451
[TBL] [Abstract][Full Text] [Related]
5. [Monoclonal antibodies in the therapy of non-resectable pancreatic cancers. Initial experiences].
Muhrer KH; Büchler M; Lucks A; Süss D; Klapdor R; Schulz G
Chirurg; 1988 May; 59(5):328-34. PubMed ID: 3396446
[TBL] [Abstract][Full Text] [Related]
6. Phase II multicenter evaluation of prolonged murine monoclonal antibody 17-1A therapy in pancreatic carcinoma.
Weiner LM; Harvey E; Padavic-Shaller K; Willson JK; Walsh C; LaCreta F; Khazaeli MB; Kirkwood JM; Haller DG
J Immunother Emphasis Tumor Immunol; 1993 Feb; 13(2):110-6. PubMed ID: 8318495
[TBL] [Abstract][Full Text] [Related]
7. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy.
Kosmas C; Snook D; Gooden CS; Courtenay-Luck NS; McCall MJ; Meares CF; Epenetos AA
Cancer Res; 1992 Feb; 52(4):904-11. PubMed ID: 1737353
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibody CO17-1A and leukapheresis in immunotherapy of pancreatic cancer.
Tempero MA; Pour PM; Uchida E; Herlyn D; Steplewski Z
Hybridoma; 1986 Jul; 5 Suppl 1():S133-8. PubMed ID: 3744378
[TBL] [Abstract][Full Text] [Related]
9. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma.
Weiner LM; Moldofsky PJ; Gatenby RA; O'Dwyer J; O'Brien J; Litwin S; Comis RL
Cancer Res; 1988 May; 48(9):2568-73. PubMed ID: 3128400
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of cell mediated immunity in advanced pancreatic carcinoma before and after treatment with interleukin-2 (IL-2).
Abdel-Wahab M; El-Shennawy F; Agha S; Ragab E; Fathi O; Sultan A; Elghawalby N; Ezzat F
Hepatogastroenterology; 1999 May; 46 Suppl 1():1293-6. PubMed ID: 10429977
[TBL] [Abstract][Full Text] [Related]
11. Treatment of advanced measurable or evaluable pancreatic carcinoma with 17-1A murine monoclonal antibody alone or in combination with 5-fluorouracil, adriamycin and mitomycin (FAM).
Paul AR; Engstrom PF; Weiner LM; Steplewski Z; Koprowski H
Hybridoma; 1986 Jul; 5 Suppl 1():S171-4. PubMed ID: 3527946
[TBL] [Abstract][Full Text] [Related]
12. Human monoclonal anti-idiotypic antibodies as an epitope vaccine against pancreatic carcinoma.
Bosslet K; Büchler M; Klapdor R; Muhrer C; Sedlacek HH; Schulz G
Behring Inst Mitt; 1988 Apr; (82):193-6. PubMed ID: 3261582
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical trial of CO17-1A monoclonal antibody.
Lobuglio AF; Saleh M; Peterson L; Wheeler R; Carrano R; Huster W; Khazaeli MB
Hybridoma; 1986 Jul; 5 Suppl 1():S117-23. PubMed ID: 3488950
[TBL] [Abstract][Full Text] [Related]
15. [Immunoscintigraphy of colorectal cancers and specific immunotherapy of pancreatic cancers using monoclonal antibodies].
Bosslet K; Schwarz A; Steinstraesser A; Kuhlmann L; Seidel L; Schulz G
Wien Med Wochenschr; 1988 Jun; 138(11-12):255-7. PubMed ID: 3262953
[TBL] [Abstract][Full Text] [Related]
16. Biologic effects of gamma interferon pre-treatment followed by monoclonal antibody 17-1A administration in patients with gastrointestinal carcinoma.
Weiner LM; Steplewski Z; Koprowski H; Sears HF; Litwin S; Comis RL
Hybridoma; 1986 Jul; 5 Suppl 1():S65-77. PubMed ID: 3091476
[TBL] [Abstract][Full Text] [Related]
17. Percolation and binding of MAB BW 494 to pancreatic carcinoma tissues during high dose immunotherapy and consequences for future therapy modalities.
Bosslet K; Keweloh HC; Hermentin P; Muhrer KH; Sedlacek HH; Schulz G
Behring Inst Mitt; 1990 Dec; (87):68-75. PubMed ID: 2096821
[TBL] [Abstract][Full Text] [Related]
18. Radioimmunodetection with 111In-labeled monoclonal antibody Nd2 in patients with pancreatic cancer.
Chung YS; Sawada T; Kondo Y; Hirayama K; Inui A; Yamashita Y; Nakata B; Okamura T; Ochi H; Ho JJ; Kim YS; Sowa M
Jpn J Cancer Res; 1997 Apr; 88(4):427-34. PubMed ID: 9197537
[TBL] [Abstract][Full Text] [Related]
19. Immunoscintigraphy and radioimmunotherapy in patients with pancreatic carcinoma.
Montz R; Klapdor R; Rothe B; Heller M
Nuklearmedizin; 1986 Dec; 25(6):239-44. PubMed ID: 3027672
[TBL] [Abstract][Full Text] [Related]
20. Human pancreatic cancer-associated antigens detected by murine monoclonal antibodies.
Yuan SZ; Ho JJ; Yuan M; Kim YS
Cancer Res; 1985 Dec; 45(12 Pt 1):6179-87. PubMed ID: 4063969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
